Drugs / VRC-MALMAB0100-00-AB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04206332 | Jan 2020 → Feb 2022 | malaria | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC-MALMAB0100-00-AB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04206332 ↗ |
| Modality | Monoclonal antibody | “VRC-MALMAB0100-00-AB (CIS43LS) is a monoclonal antibody” NCT04206332 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT04206332 ↗ |